Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Presentation

Poster: Highly Specific Zinc Finger Proteins with Synthetic Target Sites Enable Self-Regulated Expression of Dosage-Sensitive Transgenes

Download PDF